An analysis of the TAILORx trial has revealed early, but not sustained, cognitive decline among breast cancer patients treated with adjuvant chemoendocrine therapy relative to endocrine therapy alone.
Research suggests that women who use hormone-modulating breast cancer treatments such as tamoxifen or aromatase inhibitors may experience a reduced risk for neurodegenerative disease.
Findings from a UK feasibility study suggest that continuous glucose monitoring is an acceptable approach for older people with diabetes and memory problems, but devices with automated transfer of glucose readings may be needed to improve completeness of data capture.
Poor attenuation of the default mode network regions of the brain may contribute to cognitive impairments in patients with systemic lupus erythematosus, say UK researchers.
Frailty appears to modify the relationship between Alzheimer’s disease pathology and Alzheimer’s dementia, with increased levels making people more susceptible to clinical disease.
The findings from two studies published in JAMA show the benefits of initial disease-modifying therapy and nonmyeloablative haematopoietic stem cell transplantation in delaying conversion to secondary progressive multiple sclerosis.
Rituximab treatment may reduce and delay disability progression in patients with secondary progressive multiple sclerosis, show findings from a comprehensive real-world cohort study.
The oromucosal cannabinoid spray nabiximols has had a positive effect on spasticity symptoms in patients with motor neuron disease in a proof-of-concept trial.
US researchers have used population-based data to predict an individual’s absolute risk of developing cognitive impairment according to imaging-based biomarkers of amyloid and neuronal injury.
Dementia is the proximate cause of death in 70% of older adults with Down’s syndrome, show findings from a large community-based study published in JAMA Neurology.
Elevated cerebrospinal fluid neurofilament light levels are associated with an increased risk of mild cognitive impairment, indicate findings from a population-based study.
High-income countries currently have the highest rates of motor neuron diseases worldwide, and the burden is increasing with the ageing population, shows an analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study 2016.
Switching from dopamine agonists to levodopa-carbidopa slow-release formulations reduces impulse control disorders in patients with Parkinson’s disease, shows a multicentre study.
The benefits of medicinal cannabinoids for the treatment of spasticity, pain and bladder dysfunction in patients with multiple sclerosis may be limited, suggests a systematic review and meta-analysis.
The insulin-like growth factor-1 pathway may be a suitable treatment target for patients with spinal and bulbar muscular atrophy, suggest preliminary findings.
Study findings show an increased risk of dementia in older people with atrial fibrillation and support the use of anticoagulants to reduce the likelihood.